Giant gains for Hologic; Smith & Nephew held back by DoJ probe
This article was originally published in Clinica
Executive Summary
Cardiac ablation specialist AtriCure succeeded in narrowing its loss by 17% on the back of healthy gains in revenue. The West Chester, Ohio-based firm's top-line was boosted by a 28% increase in sales of its minimally-invasive products and a 22% increase in sales of its open-heart technology in the US. However, these gains were outweighed by research and development costs, and administrative expenses, resulting in an overall loss of $2.6m. AtriCure has narrowed its revenue outlook for 2007 to $48-48.7m and lowered its loss per share forecast to a range of 92-97 cents per share.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.